Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells.
about
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenograftsVascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the diseasePhysical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.The B-cell receptor signaling pathway as a therapeutic target in CLL.Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of SapacitabinePreclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the tradeNF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalingMolecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques.B cell receptor signaling in chronic lymphocytic leukemia.Mechanism and Function of Angiogenin in Hematopoietic Malignancy.Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia.Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2.Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2.
P2860
Q33607950-77B21C30-34D9-4D35-808B-9E48A53081FEQ33618949-AE6F2962-F8E7-4FFD-941D-234D0B415638Q33817641-E6695CF1-84C7-416A-B19A-E4DA05E67163Q34081881-AFF1148E-25BC-498C-9974-0FD57B9CA0DEQ34184717-F6F13CD1-682A-4CA0-964F-B8427CAACA8DQ34419599-A44033A4-5F34-4F19-8206-B4536A939D6EQ34671934-9782643B-94E4-4D51-B4E7-37DB3C74E01FQ35082524-2994895A-D4F7-44B1-8248-F55AF4022F77Q36006453-C44A22E4-6F7D-46C6-B62A-ADBD226645EBQ36163034-D820C7DB-ABCB-4B88-BBCD-8CAD54284803Q36289307-235E9CB2-BE60-4B0F-8EBA-7A9D427CE128Q36867755-2B75D8C4-A84A-4AA2-A610-915EDE9C637FQ37605861-36D24284-54BD-4AF0-8A87-912BCF06BB46Q37959298-4B388855-C0BD-44A7-9EC5-0B34A67F4B1AQ38069567-512BDFC0-5482-473C-AFE8-09A73BAF0C70Q38095551-CC8D56CC-8DE8-4AA0-8723-D306492E17A1Q38127513-EA509DDA-747F-4386-8EE6-E02A187A66ADQ38366707-B59CB29F-2B8D-45EB-8365-2B5AAFFBC6AFQ38616463-859383C1-920E-421B-9212-52E1EA02C5C9Q38689750-9E4057DF-9BBC-49EB-A626-1D1DB29E99ECQ38823622-D83D355F-6F6C-41A4-B2D7-B068BD35FC14Q39339803-B26DF1E0-C528-4696-94F5-81D3497E40C9Q39798268-7EAA7439-C544-488B-9AB8-0BCC94CC1E9AQ42191925-F460E2C5-DD24-4F9D-9860-7AB42734F03CQ42638970-C07738AD-6D7C-4FE3-86F9-F6AF131DAC13Q47710385-C83DA92B-DFBF-4039-8F33-FF377EDC726DQ54584717-AB703054-DDE0-457D-AEDD-A08F6038C2ED
P2860
Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Bone marrow fibroblasts induce ...... ogenic phenotype in CLL cells.
@en
Bone marrow fibroblasts induce ...... ogenic phenotype in CLL cells.
@nl
type
label
Bone marrow fibroblasts induce ...... ogenic phenotype in CLL cells.
@en
Bone marrow fibroblasts induce ...... ogenic phenotype in CLL cells.
@nl
prefLabel
Bone marrow fibroblasts induce ...... ogenic phenotype in CLL cells.
@en
Bone marrow fibroblasts induce ...... ogenic phenotype in CLL cells.
@nl
P2093
P1433
P1476
Bone marrow fibroblasts induce ...... ogenic phenotype in CLL cells.
@en
P2093
A Carpinteiro
J Edelmann
L Klein-Hitpass
L Sellmann
S Stilgenbauer
P304
P356
10.1016/J.LEUKRES.2008.03.003
P577
2008-04-14T00:00:00Z